Literature DB >> 2786529

A monoclonal antibody to the IL-1 beta peptide 163-171 blocks adjuvanticity but not pyrogenicity of IL-1 beta in vivo.

D Boraschi1, G Volpini, L Villa, L Nencioni, G Scapigliati, D Nucci, G Antoni, G Matteucci, F Cioli, A Tagliabue.   

Abstract

The synthetic fragment VQGEESNDK, corresponding to the amino acid sequence in position 163-171 of human IL-1 beta, possesses the immunostimulatory but not the pyrogenic activity of the mature IL-1 beta polypeptide in vivo. To assess the relevance of this domain of IL-1 beta for its biologic activities, a mAb was raised against the synthetic peptide 163-171. The mAb Vhp20 could effectively recognize human rIL-1 beta in RIA and immunoblotting. In vivo, the mAb Vhp20 was able to selectively inhibit the immunostimulatory activity of IL-1 beta, but it could not affect the fever-inducing capacity of IL-1 beta. It is proposed that functional domains could be identified in the human IL-1 beta protein and that the fragment in position 163-171 is of major importance for the adjuvant capacity of the entire molecule, but irrelevant to its pyrogenic activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786529

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  A role for protein kinase C activity in interleukin-1 (IL-1) induction of IL-2 gene expression but not in IL-1 signal transduction.

Authors:  G Macchia; C T Baldari; A Massone; J L Telford
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

2.  Interferon-gamma potentiates antibody affinity in mice with a genetically controlled defect in affinity maturation.

Authors:  G P Holland; N Holland; M W Steward
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Comparison of abilities of recombinant interleukin-1 alpha and -beta and noninflammatory IL-1 beta fragment 163-171 to upregulate C3b receptors (CR1) on human neutrophils and to enhance their phagocytic capacity.

Authors:  J D Ogle; J G Noel; A Balasurbramaniam; R M Sramkoski; C K Ogle; J W Alexander
Journal:  Inflammation       Date:  1990-04       Impact factor: 4.092

4.  In vivo expression of interleukin-1 beta (IL-1 beta), IL-2, IL-4, IL-6, tumour necrosis factor-alpha and interferon-gamma in the fetal murine thymus.

Authors:  J Deman; M Van Meurs; E Claassen; C Humblet; J Boniver; M P Defresne
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

5.  Cytokine production (IL-1 alpha, IL-1 beta, and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin's disease, and in non-Hodgkin's lymphomas. An immunocytochemical study.

Authors:  L P Ruco; D Pomponi; R Pigott; A Stoppacciaro; F Monardo; S Uccini; D Boraschi; A Tagliabue; A Santoni; E Dejana
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

6.  Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis.

Authors:  M N Farahat; G Yanni; R Poston; G S Panayi
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

7.  Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture.

Authors:  J N Palmer; W E Hartogensis; M Patten; F D Fortuin; C S Long
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

8.  Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane.

Authors:  G Yanni; M Nabil; M R Farahat; R N Poston; G S Panayi
Journal:  Ann Rheum Dis       Date:  1994-05       Impact factor: 19.103

9.  Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration.

Authors:  G Yanni; A Whelan; C Feighery; W Quinlan; J Symons; G Duff; B Bresnihan
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

10.  Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1.

Authors:  K V Rao; A R Nayak
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.